Skip to main navigation Skip to search Skip to main content

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

  • Carl C. Peck
  • , William H. Barr
  • , Leslie Z. Benet
  • , Jerry Collins
  • , Robert E. Desjardins
  • , Daniel E. Furst
  • , John G. Harter
  • , Gerhard Levy
  • , Thomas Ludden
  • , John H. Rodman
  • , Lilly Sanathana
  • , Jerome J. Schentag
  • , Vinod P. Shah
  • , Lewis B. Sheiner
  • , Jerome P. Skelly
  • , Donald R. Stanski
  • , Robert J. Temple
  • , C. T. Viswanathan
  • , Judi Weissinger
  • , Avraham Yacobi
  • United States Food and Drug Administration
  • Virginia Commonwealth University
  • University of California at San Francisco
  • American Cyan-amid Co
  • Ciba-Geigy Pharmaceuticals
  • SUNY Buffalo
  • St. Jude Children Research Hospital
  • VA Medical Center

Research output: Contribution to journalArticlepeer-review

194 Scopus citations

Abstract

Clinical Pharmacology and Therapeutics (1992) 51, 465–473; doi:

Original languageEnglish
Pages (from-to)465-473
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume51
Issue number4
DOIs
StatePublished - Apr 1992

Fingerprint

Dive into the research topics of 'Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development'. Together they form a unique fingerprint.

Cite this